Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.55 |
| ▸ | KDR | P35968 | 6/20 | 0.35 |
| ▸ | PI4KA | P42356 | 3/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | XDH | P47989 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | TEK | Q02763 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL946620 | 0.77 | ADORA2A (0.56) | ADORA2AADORA1KDRPI4KAPI4K2B | |
| SCHEMBL18076190 | 0.77 | ADORA2A (0.56) | ADORA2AADORA1KDRPI4KAPI4K2B | |
| SCHEMBL15942468 | 0.75 | ADORA2A (0.55) | ADORA2AADORA1KDRPI4KAPI4K2B | |
| SCHEMBL12699730 | 0.75 | ADORA2A (0.55) | ADORA2AADORA1KDRPI4KAPI4K2B | |
| SCHEMBL26976 | 0.75 | ADORA2A (0.61) | ADORA2AADORA1KDRPI4KAPI4K2B | |
| SCHEMBL1665392 | 0.72 | ADORA2A (0.71) | ADORA2AADORA1KDRPI4KAPI4K2B | |
| SCHEMBL756635 | 0.71 | ADORA2A (1.00) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL31065859 | 0.71 | ADORA2A (0.54) | ADORA2AADORA1KDRPI4KAPI4K2B | |
| SCHEMBL31060798 | 0.71 | ADORA2A (1.00) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1665301 | 0.71 | ADORA2A (0.69) | ADORA2AADORA1KDRPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245479-A1 | Method for Generating Aptamers with Improved Off-Rates | SOMALOGIC, INC. (US) | 2011-10-06 | — | — | US | claimed |
| EP-2069529-A2 | METHOD FOR GENERATING APTAMERS WITH IMPROVED OFF-RATES | Somalogic, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| WO-2009012418-A2 | METHOD FOR GENERATING APTAMERS WITH IMPROVED OFF-RATES | SOMALOGIC, INC. (US) | 2009-01-22 | — | — | WO | claimed |
| US-20090004667-A1 | METHOD FOR GENERATING APTAMERS WITH IMPROVED OFF-RATES | SOMALOGIC, INC. (US) | 2009-01-01 | — | — | US | claimed |
| EP-1994171-A2 | MULTIPLEXED ANALYSES OF TEST SAMPLES | SomaLogic, Inc. (US) | 2008-11-26 | — | — | EP | claimed |
| EP-1889910-A2 | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex | SomaLogic, Inc. (US) | 2008-02-20 | — | — | EP | claimed |
| EP-0736105-B1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS | SOMALOGIC INC (US) | 2007-11-21 | — | — | EP | claimed |
| WO-2007084886-A2 | MULTIPLEXED ANALYSES OF TEST SAMPLES | SOMALOGIC, INCORPORATED (US) | 2007-07-26 | — | — | WO | claimed |
| US-20070166740-A1 | MULTIPLEXED ANALYSES OF TEST SAMPLES | SOMALOGIC, INCORPORATED (US) | 2007-07-19 | — | — | US | claimed |
| US-20070166741-A1 | MULTIPLEXED ANALYSES OF TEST SAMPLES | SOMALOGIC, INCORPORATED (US) | 2007-07-19 | — | — | US | claimed |
| WO-2002077262-A2 | METHOD AND APPARATUS FOR THE AUTOMATED GENERATION OF NUCLEIC ACID LIGANDS | SOMALOGIC, INC. (US) | 2002-10-03 | — | — | WO | claimed |
| US-20020106652-A1 | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex | SOMALOGIC, INC. | 2002-08-08 | — | — | US | claimed |
| EP-0739898-B1 | Phosphonomonoester nucleic acids, methods for their preparation and their use | AVENTIS PHARMA GMBH (DE) | 2001-09-26 | — | — | EP | claimed |
| US-6001577-A | SCREENING FOR LIGANDS ASSOCIATED WITH A DISEASE BY DETECTING LIGAND THAT PHOTOCROSSLINKS TO TARGET WITH PHOTOREACTIVE GROUPS FROM CANDIDATE MIXTURE, REMOVING ANY NUCLEIC ACIDS WITH AFFINITIES NOT ASSOCIATED WITH DISEASE, AND AMPLIFYING | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-12-14 | — | — | US | claimed |
| US-5874553-A | ANTIBODIES; INHIBITOR OF GENE EXPRESSION | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-02-23 | — | — | US | claimed |
| EP-0736105-A4 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX | UNIV RESEARCH CORP (US) | 1998-10-28 | — | — | EP | claimed |
| US-5763177-A | SELEX IS AN ACRONYM FOR SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT; USEFUL FOR DIAGNOSIS AND/OR TREATMENT OF DISEASES OR PATHOLOGICAL OR TOXIC STATES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-06-09 | — | — | US | claimed |
| EP-0739898-A2 | Phosphonomonoester nucleic acids, methods for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-10-30 | — | — | EP | claimed |
| EP-0736105-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX | NeXstar Pharmaceuticals, Inc. (US) | 1996-10-09 | — | — | EP | claimed |
| WO-1995008003-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX | UNIVERSITY RESEARCH CORPORATION (US) | 1995-03-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245479-A1 | Method for Generating Aptamers with Improved Off-Rates | DDX1, DDX3X, DDX18 | ADORA2A 481/4885ADORA1 913/4885KDR 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.